Roche has talked for a long time about pursuing innovation rather than branded generics in emerging markets. But investors and other stakeholders have openly wondered how Roche could do that and still make its drugs affordable to the majority of patients in countries like China, India and other emerging markets.
During its Feb. 1 and Feb. 3 quarterly earnings call from London and New York, respectively, Roche for the first...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?